4.89
+0.12(+2.52%)
Currency In USD
| Previous Close | 4.77 |
| Open | 4.77 |
| Day High | 5.09 |
| Day Low | 4.68 |
| 52-Week High | 5.1 |
| 52-Week Low | 0.65 |
| Volume | 1.5M |
| Average Volume | 854,150 |
| Market Cap | 337.23M |
| PE | -2.51 |
| EPS | -1.95 |
| Moving Average 50 Days | 2.87 |
| Moving Average 200 Days | 1.84 |
| Change | 0.12 |
If you invested $1000 in Opus Genetics, Inc. (IRD) since IPO date, it would be worth $349.04 as of March 08, 2026 at a share price of $4.89. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 1 year ago, it would be worth $3,790.7 as of March 08, 2026 at a share price of $4.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in p
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
GlobeNewswire Inc.
Feb 27, 2026 3:10 PM GMT
Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and structural improvement observed at one month and thre
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
GlobeNewswire Inc.
Feb 25, 2026 11:59 AM GMT
FDA PDUFA Goal Date Set for October 17, 2026RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies t